Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12553325 | 0.88 | CNR2 (0.50) | CNR2ERN1 | |
| SCHEMBL12581548 | 0.86 | LMNA (0.61) | LMNACNR2ERN1 | |
| SCHEMBL5433882 | 0.85 | FFAR1 (0.47) | LMNACES2CES1HPGDTSHR | |
| SCHEMBL4174720 | 0.83 | CYP1A1 (0.61) | LMNACES2CES1CYP1A2CYP3A4 | |
| SCHEMBL4167549 | 0.82 | CYP1A2 (0.67) | LMNACES2CES1CYP1A2CYP3A4 | |
| SCHEMBL16712927 | 0.81 | HSD17B2 (0.60) | LMNACES2CES1CYP1A2CYP3A4 | |
| SCHEMBL12581547 | 0.80 | NPC1 (0.56) | POLBHPGDTSHRHSD17B2MAPK1 | |
| SCHEMBL10316380 | 0.78 | CYP1A2 (0.54) | CYP1A2CYP3A4POLBERN1TSHR | |
| SCHEMBL29626810 | 0.77 | CES2 (0.71) | CES2CES1TSHRPARP1ABCG2 | |
| SCHEMBL24402 | 0.77 | CES2 (0.71) | CES2CES1TSHRPARP1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461207-B2 | Phloroglucinol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8461207-B2 | Phloroglucinol derivatives having selectin ligand activity | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8278356-B2 | — | — | 2012-10-02 | — | — | US | disclosed |
| US-8278356-B2 | — | — | 2012-10-02 | — | — | US | disclosed |
| US-20110142765-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110142765-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-06-16 | — | — | US | disclosed |
| US-7919532-B2 | Chronic onstructive pulmonary disease; adult respiratory distress syndrome; antiinflammatory agents; skin disorders; autoimmune diseases; multiple sclerosis; antihistamines; inflammatory bowel disorders | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | disclosed |
| US-7919532-B2 | Chronic onstructive pulmonary disease; adult respiratory distress syndrome; antiinflammatory agents; skin disorders; autoimmune diseases; multiple sclerosis; antihistamines; inflammatory bowel disorders | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | disclosed |
| US-7919532-B2 | Chronic onstructive pulmonary disease; adult respiratory distress syndrome; antiinflammatory agents; skin disorders; autoimmune diseases; multiple sclerosis; antihistamines; inflammatory bowel disorders | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | disclosed |
| US-20080207741-A1 | Novel Hydroxylated Aromatic Compounds | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207741-A1 | Novel Hydroxylated Aromatic Compounds | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207741-A1 | Novel Hydroxylated Aromatic Compounds | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1937237-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | Revotar Biopharmaceuticals AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039112-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039112-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207741-A1 | Novel Hydroxylated Aromatic Compounds | SELP, SELL, SELE | LMNA 1265/4885CNR2 2642/4885CES2 244/4885 |
| US-20110142765-A1 | NOVEL PHLOROGLUCINOL DERIVATIVES HAVING SELECTIN LIGAND ACTIVITY | SELPLG, SELP, SELL | LMNA 2533/4885CNR2 3666/4885CES2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.